TERT and central nervous system cancer: In gliomas, the prevalence of mutations on the TERT promoter is remarkably high in primary GBMs (approximately 80%) (Figure 3A) [96], and recent evidence suggested the presence of TERT promoter mutations as an unfavorable prognostic factor in GBM [97].